GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成修饰肽 | 39 个氨基酸，含脂肪酸侧链 |
| 受体靶点 | GIP 与 GLP-1 受体 | 双重激动剂 |
| 分子量 | 约 4.8 kDa | 以游离肽计 |
| 外观 | 白色至类白色粉末 | 冻干形态常见 |
| 溶解性 | 可溶于水及水性缓冲液 | 溶解后宜低温保存 |
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
The Druze faith extended to many areas in the Middle East, but most of the modern Druze can trace their origin to the Wadi al-Taym in Southern Lebanon, which is named after an Arab tribe Taym Allah (or Taym Allat) which, according to Islamic historian al-Tabari, first came from the Arabian Peninsula into the valley of the Euphrates where they had been Christianized prior to their migration into Lebanon. Many of the Druze feudal families, whose genealogies have been preserved by the two modern Syrian chroniclers Haydar al-Shihabi and Ahmad Faris al-Shidyaq, seem also to point in the direction of this origin. Arabian tribes emigrated via the Persian Gulf and stopped in Iraq on their route that would later to lead them to Syria. The first feudal Druze family, the Tanukhids, which made for itself a name in fighting the Crusaders was, according to Haydar al-Shihabi, an Arab tribe from Mesopotamia where it occupied the position of a ruling family and apparently was Christianized. Until the Christian Crusaders arrived in the Holy Land in 1099, there is scant recorded history of the Druze. However, when they do emerge in accounts of the Christian occupation of the Levant, they are depicted as fierce warriors dedicated to repelling the Crusader armies. In the 17th century, there was a prevailing belief in France that the Druze were descendants of a lost army of European Christian crusaders.
== Safety == Good clinical compliance was observed at the typical clinical oral dose of 150 mg/day, with no symptomatic side effect reported. The adverse event rate was higher at high dose zinc L-carnosine (300 mg/day) without additional benefits, and therefore high dose is not recommended. Side-effects are associated with the amount of zinc intake. According to the Japanese product monograph, safety in children below the age of 12, pregnant women and lactating women are not established (no experience in use); and the level of use in the elderly population is suggested and recommended at 100 mg zinc L-carnosine per day because of reduced digestive system function in the general elderly population; and those with poor liver functions should be under medical supervision. Those with copper deficiency should also be under medical supervision. Although zinc L-carnosine caused an increase in serum zinc level, the serum copper level and copper:zinc ratio decreased, and a case of preexisting copper deficiency deteriorated. As a mitigative, supplementation of 2 mg/day copper as glycinate chelate safely increases Cu-Zn superoxide dismutase activity. There is no evidence of a reduced tumor response to radiotherapy.
== Clinical significance == Guanine nucleotide synthesis is essential for maintaining normal cell function and growth, and is also important for the maintenance of cell proliferation and immune responses. IMPDH expression is found to be upregulated in some tumor tissues and cell lines. B and T lymphocytes display a dependence on IMPDH for normal activation and function, and demonstrate upregulated IMPDH expression. Therefore, IMPDH has been addressed as a drug target for immunosuppressive and cancer chemotherapy. Mycophenolate is an immunosuppressant that is used to prevent transplant rejection and acts through inhibition of IMPDH. Mycophenolate mofetil has been shown to inhibit completely both vaccinia and monkeypox viruses. Mutations in the Bateman domain of IMPDH1 are associated with the RP10 form of autosomal dominant retinitis pigmentosa and dominant Leber's congenital amaurosis.
=== Bolesław I the Brave === Mieszko's son, Duke Bolesław I the Brave (r. 992–1025), established a Polish Church structure, pursued territorial conquests and was officially crowned the first king of Poland in 1025, near the end of his life. Bolesław also sought to spread Christianity to parts of eastern Europe that remained pagan, but suffered a setback when his greatest missionary, Adalbert of Prague, was killed in Prussia in 997. During the Congress of Gniezno in the year 1000, Holy Roman Emperor Otto III recognized the Archbishopric of Gniezno, an institution crucial for the continuing existence of the sovereign Polish state. During the reign of Otto's successor, Holy Roman Emperor Henry II, Bolesław fought prolonged wars with the Kingdom of Germany between 1002 and 1018.
Sources: en.wikipedia.org
=== Tonus Therapeutics === After completing his formal education, Sachs taught organic chemistry at Chaminade College School followed by a position as a staff fellow at the National Institutes of Health. In 1978, he accepted an assistant professor position in the University at Buffalo's Department of Pharmacology. In this role, Sachs discovered mechanosensitive ion channels which are sensors for systems including the senses of hearing, touch, and balance. As a result of his discovery, he also created the only drug to inhibit these channels. Sachs believed that spider venom could contain molecular compounds that could block the ion channels. After discovering the possibility of a drug, he was contacted by several large pharmaceutical companies but none offered to adopt the drug. He eventually co-launched Rose Pharmaceuticals in 2009, which was named after Sachs’ pet tarantula and grandmother, with a stockbroker named Harvey whose grandson had had Duchenne muscular dystrophy. The following year, the Food and Drug Administration designated the firm’s peptide, called GsMTx4, as an orphan drug for Duchenne muscular dystrophy. In 2012, Sachs and Harvey opened their first-ever headquarters in UB’s New York State Center of Excellence in Bioinformatics and Life Sciences and re-named the company Tonus Therapeutics. Within two years, the company sold the rights to their drug to Akashi Therapeutics. He also began studying AT-300’s effectiveness in dystrophic mice.
=== Occurrence in space === Nitriles are among the most abundant organic molecules in space, and more than ten distinct compounds have been unequivocally detected. Hydrogen cyanide was one of the first polyatomic species identified in space and occurs there relatively frequently and in substantial quantities. Other nitriles detected in space include acetonitrile and aminoacetonitrile, as well as butyronitrile, cyanoacetylene, and cyanopolyins containing two to five conjugated triple bonds. Hydrogen cyanide, cyanoacetylene, and cyanogen are present in the atmosphere of Saturn's moon Titan.
=== Alkylation, acylation, and sulfonation, etc. === Aside from their basicity, the dominant reactivity of amines is their nucleophilicity. Most primary amines are good ligands for metal ions to give coordination complexes. Amines are alkylated by alkyl halides. Acyl chlorides and acid anhydrides react with primary and secondary amines to form amides (the "Schotten–Baumann reaction").
Sources: en.wikipedia.org
The galactic year, GY, is the time it takes the Solar System to revolve once around the galactic core, approximately 250 million years (megaannum or "Ma"). It is a convenient unit for long-term measurements. For example, oceans appeared on Earth after 4 GY, life is detectable at 5 GY, and multicellular organisms first appeared at 15 GY. The age of the Earth is estimated at 20 GY. This use of GY is not to be confused with Gyr for gigayear or Gy for Gray (unit).
Restriction of energy intake relative to requirements leading to a low body weight. (Criterion A) Intense fear of gaining weight or persistent behaviors that interfere with gaining weight. (Criterion B) Disturbance in the way a person's weight or body shape is experienced or a lack of recognition about the risks of the low body weight. (Criterion C) Relative to the previous version of the DSM (DSM-IV-TR), the 2013 revision (DSM-5) reflects changes in the criteria for anorexia nervosa. Most notably, the amenorrhea (absent period) criterion was removed. Amenorrhea was removed for several reasons: it does not apply to males, it is not applicable for females before the age of menstruation, during or after the menopause, or women of any age taking birth control. Additionally, some women who meet the other criteria for AN still report some menstrual activity.
The new 7th district encompasses a diverse southwestern stretch of the Greater Houston area across Harris and Fort Bend counties, including the Galleria area of Houston and the inner West Loop neighborhoods of Montrose, Meyerland, Rice Military, the Heights and Greenway Plaza, along with such diverse southwest Houston neighborhoods as Westchase, Sharpstown, Gulfton and Alief, and largely Asian and Hispanic portions of western Sugar Land and Mission Bend in Fort Bend County. The incumbent is Democrat Lizzie Fletcher, who was re-elected with 61.2% of the vote in 2024. The diverse district gave 60.3% to Kamala Harris and 63.1% to Colin Allred in 2024.
Sources: en.wikipedia.org
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。
分子上的脂肪酸侧链使其与血浆白蛋白结合增强，显著延长循环半衰期。半衰期延长后，稳定血药浓度可在较长的给药间隔内维持，因此常见用法为每周一次。
同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比，临床研究中观察到的血糖与体重变化幅度通常更明显，但各通路的具体贡献比例尚无定论。
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.